Article info
PDFClinical and epidemiological research
Concise report
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
- Correspondence to Dr Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité–University Medicine Berlin, Charitéplatz 1, Berlin 10017, Germany; gerd.burmester{at}charite.de
Citation
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
Publication history
- Received February 2, 2016
- Revised April 25, 2016
- Accepted May 27, 2016
- First published June 23, 2016.
Online issue publication
January 10, 2017
Article Versions
- Previous version (23 June 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/